We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Randomised clinical trial: the effectiveness of Gaviscon Advance vs non‐alginate antacid in suppression of acid pocket and post‐prandial reflux in obese individuals after late‐night supper.
- Authors
Deraman, Mohd Adli; Abdul Hafidz, Muhammad Ilham; Lawenko, Rona Marie; Ma, Zheng Feei; Wong, Mung Seong; Coyle, Cathal; Lee, Yeong Yeh
- Abstract
Summary: Background: Late‐night supper increases the risk of postprandial reflux from the acid pocket especially in obesity. An alginate‐based, raft‐forming medication may be useful for obese patients with GERD. Aims: To compare the efficacy of Gaviscon Advance (Reckitt Benckiser, UK) and a non‐alginate antacid in post‐supper suppression of the acid pocket and post‐prandial reflux among obese participants. Methods: Participants underwent 48 h wireless and probe‐based pH‐metry recording of the acid pocket and lower oesophagus, respectively, and were randomised to single post‐supper (10 pm) dose of either Gaviscon Advance or a non‐alginate antacid on the second night. Primary outcomes were suppression of median pH of acid pocket and lower oesophagus, measured every 10‐minutes post‐supper for 1 h. Secondary outcomes were suppression of % time pH < 4 at lower oesophagus and improvement in frequency and visual analogue score (VAS) of regurgitation. Results: Of the 81 screened participants, 55 were excluded and 26 (mean age 33.5 years, males 77.8% and BMI 32.8 kg/m2) were randomised to Gaviscon Advance (n = 13) or antacid (n = 13). Median pH of the acid pocket but not the lower oesophagus was suppressed with Gaviscon Advance vs antacid (all P < 0.04) Gaviscon Advance but not antacid significantly reduced in % time pH < 4, symptom frequency and VAS on day 2 vs day 1 (all P < 0.05). Conclusions: Among obese individuals, Gaviscon Advance was superior to a non‐alginate antacid in post‐supper suppression of the acid pocket. (Clinical trial registration unique identifier: NCT03516188).
- Subjects
UNITED Kingdom; RECKITT Benckiser Group PLC; CLINICAL trial registries; ANTACIDS; CLINICAL trials; SUPPERS; ESOPHAGUS; ALGINATES
- Publication
Alimentary Pharmacology & Therapeutics, 2020, Vol 51, Issue 11, p1014
- ISSN
0269-2813
- Publication type
Article
- DOI
10.1111/apt.15746